Late-breaking oral presentation will discuss the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis and other diseases involving the IL-13 and IL-31 pathways ZL-1503 is ...
The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...
(RTTNews) - CymaBay Therapeutics Inc. (CBAY), on Wednesday, announced new published data from a post-hoc analysis of its phase III ENHANCE study of Seladelpar demonstrating a correlation between itch ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback